Prix Galien USA: Domain Therapeutics Nominated for the Prestigious Best Startup Award
This nomination underscores the innovative essence of Domain’s precision-driven approach and highlights the remarkable progress and promise of our unique pipeline of G Protein-Coupled Receptor (GPCR)-targeting drug candidates. Among 43 pioneering companies and industry leaders, including fifteen from France, Domain stands out for its groundbreaking work in a category that celebrates the most innovative and impactful companies in the biotech industry.
Prix Galien: honoring excellence in scientific discovery and innovation
The Prix Galien, often regarded as the Nobel Prize in biopharmaceutical research, honors the exceptional achievements in improving human health through the development of innovative therapies and technologies. Established in 1970 by Roland Mehl in honor of Galen, the father of medical science and modern pharmacology, this prestigious award emphasizes the crucial importance of consistently pushing the boundaries of medical science to shape the future of medicine.
We are at the forefront of precision science and innovation
This nomination highlights the significance of the groundbreaking work being done by our teams and peers in the industry in enhancing clinical research and developing more advanced and effective treatment options for patients.
GPCRs are instrumental in drug discovery, accounting for 30% of all marketed drugs, yet their full potential remains untapped. For over two decades, Domain has led GPCR drug discovery, transforming therapeutic target identification to deliver more effective therapeutic solutions for patients.
Our journey began in 2008 with a strong belief that our differentiated, science-led innovation can make a real difference in patients’ lives, providing them with high-quality medicines that will raise survival expectations and clinical outcomes. This dedication to patient well-being laid the foundation for our precision-driven approach, developing groundbreaking treatments that target GPCR-mediated immunosuppression to overcome the limitations of current therapies.
“Being nominated for this prestigious award is a testament to the incredible work and dedication of our team, partners and collaborators, whose ingenuity drives our success. We share the Galien Foundation’s vision of impacting medical practice and saving lives. Our innovative approach to GPCR-targeting immunotherapies, characterized by unparalleled precision, has the potential to revolutionize the treatment landscape and deliver solutions to patients with significant unmet medical needs. We are honored to be recognized among such esteemed companies in the industry. This nomination fuels our commitment to transforming patient lives through precision science.”
Today, by combining our expertise in GPCRs and the immune system, Domain pioneers a new frontier in immuno-oncology. This synergy, still largely underexplored, offers immense promise and vast opportunities for drug development. Our validated industrial deals (Pfizer, Bristol-Myers Squibb, Merck, Ono, Boehringer Ingelheim…) and robust pipeline of GPCR-targeting drug candidates with competitive properties have shown promising results in preclinical and clinical trials.
Looking Ahead: Advancing precision science to transform lives
The future of GPCR drug discovery is inspiring, with novel drug mechanisms enabling the development of better and more effective drugs. As GPCR-targeting immunotherapies continue to validate their clinical efficacy, Domain’s innovative spirit and solid expertise in novel modalities with improved GPCR selectivity, such as Allosteric Modulator and biased ligands, reinforce our leading role in pioneering unique therapeutic strategies.
We are not alone in this journey. Advancing clinical practice standards requires close collaboration with leading experts in academia, pharma partners, and biotech companies. The Prix Galien USA nomination is a proud moment for us, offering a tremendous opportunity to engage with international investors and healthcare leaders in the United States.